Testosterone after prostate radiotherapy: symptom improvements leave safety questions open
A small cohort and review reported symptom and anemia improvements, but the evidence cannot resolve whether testosterone affects cancer recurrence.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Based on the abstract, testosterone treatment was associated with improvements in fatigue, mood and sexual symptoms after prostate cancer radiotherapy. Some men with anemia also improved. The authors described recurrence as uncommon, although metastatic disease occurred in the cohort. These observations cannot establish whether treatment changes cancer recurrence risk or causes symptom improvements.
The cohort was small, and the abstract does not describe an untreated comparison group or overall cohort follow-up. The review drew on case reports, limiting conclusions about safety and effectiveness.
What researchers tracked
The analysis tracked symptoms, anemia and cancer recurrence alongside testosterone and prostate-specific antigen. Both blood measures rose during treatment. The abstract does not provide symptom effect sizes or a comparison with similar untreated men.
Understanding the recurrence evidence
A participant developed metastatic disease 3 years after starting testosterone. The review also reported biochemical recurrences. These observations matter, but neither a low reported rate nor an isolated event establishes treatment safety or harm.
The original publication
Testosterone Replacement Therapy in Prostate Cancer Survivors Treated With Radiation With and Without Androgen Deprivation Therapy: A Retrospective Study and Narrative Review.
Chandra MS, Wang C, Gagliano-Jucá T et al.
Endocr Pract · 2026
- PubMed ID
- 41621657
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.